Synergism of Hematopoietic Cytokines for Infarct Repair
نویسندگان
چکیده
منابع مشابه
Synergism of hematopoietic cytokines for infarct repair.
Over the past few years, the field of stem cell biology and its therapeutic application in cardiovascular diseases has expanded remarkably and moved to the forefront of cardiovascular science. Promising results from experimental studies with bone marrow (BM)-derived stem or progenitor cells1–3 prompted initiation of clinical trials in ischemic heart diseases (IHD). Pilot clinical trials4,5 demo...
متن کاملHematopoietic cytokines.
The production of hematopoietic cells is under the tight control of a group of hematopoietic cytokines. Each cytokine has multiple actions mediated by receptors whose cytoplasmic domains contain specialized regions initiating the various responses-survival, proliferation, differentiation commitment, maturation, and functional activation. Individual cytokines can be lineage specific or can regul...
متن کاملCytokines and hematopoietic stem cell mobilization.
Hematopoietic stem cell transplantation (HSCT) has become the standard of care for the treatment of many hematologic malignancies, chemotherapy sensitive relapsed acute leukemias or lymphomas, multiple myeloma; and for some non-malignant diseases such as aplastic anemia and immunodeficient states. The hematopoietic stem cell (HSC) resides in the bone marrow (BM). A number of chemokines and cyto...
متن کاملMonocytes: protagonists of infarct inflammation and repair after myocardial infarction.
Myocardial infarction (MI) is the most frequent cause of heart failure, which is an incapacitating disease with high prevalence and broad socioeconomic impact. In 2008 in the United States, 5.7 million people suffered from heart failure, and more than 287 000 people died.1 Timely revascularization of ischemic myocardium reduces acute infarct mortality, and current standard therapy with blockers...
متن کاملHematopoietic stem cells for neovascularization and wound repair
Background It is now well-known that a critical part of normal healing for cutaneous wounds is the formation of new blood vessels. As implantation of autologous bone marrow (BM)-derived Endothelial Progenitor Cells (EPC) into ischemic limbs has become a promising treatment for moderate to severe peripheral arterial occlusive disease (PAD), we have begun a Phase II randomized trial in Type 2 dia...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Research
سال: 2006
ISSN: 0009-7330,1524-4571
DOI: 10.1161/01.res.0000222024.14452.7b